The University of Warwick has launched a spin-out to speed up medtech and health technology clinical trials across the UK.
VerIQ Limited aims to change how medical device and health technology trials are designed, initiated and delivered.
Formed in partnership with University Hospitals Coventry and Warwickshire (UHCW) NHS Trust, VerIQ will combine academic and clinical research expertise through an integrated national trial platform.
The company said it aims to enable faster, higher-quality and more cost-efficient evaluation of novel medical technologies.
Dr Tim Hart, director of Warwick Innovations, said: “VerIQ harnesses the success and strength of our scientific leadership and showcases the impact that academic and industry collaboration can achieve.”
“By enabling this new company to commercially leverage Warwick’s existing capabilities and expertise, we can help position the region and UK at the forefront of global Medtech innovation and evidence generation.”
The launch supports the UK government’s ambition to make the UK a destination for health technology development and evaluation, with faster adoption of innovation within the NHS.
Professor Andy Metcalfe, a Warwick Medical School academic and an orthopaedic surgeon at UHCW who is chief medical officer at VerIQ, said: “When having surgery, our patients want access to the best technology available.”
“We need to deliver world-class studies that makes the UK the first place to come to for medical innovation. VerIQ will deliver efficient, high-quality medical research to ensure that patients get access to new technologies quickly and safely, improving their care and outcomes.”
The spin-out aims to create an integrated clinical ecosystem for innovators, from early-stage start-ups to established multinational manufacturers, to design, launch and execute clinical studies.
Dr Joe Dupere, chief executive officer of VerIQ Limited, said: “The UK has the talent, infrastructure, and regulatory framework to lead the world in Medtech innovation.”
“VerIQ Limited will transform proven research excellence into an agile commercial platform, helping to ensure that life-changing technologies reach patients faster, without compromising scientific integrity.”
Initial work through VerIQ will focus on orthopaedics and wider medtech trials, combining Warwick’s academic leadership with the spin-out’s operational capacity to streamline trial start-up, accelerate participant recruitment, and deliver consistent, high-quality data.
